KyDo Therapeutics GmbH (KyDo), a preclinical-stage biotechnology company committed to developing novel covalent-allosteric small molecule inhibitors with the potential to become best-in-class oncology drugs, announced the receipt of the 2026 MATWIN award for the best drug-based innovation project in...
